Morning Briefing
Summaries of health policy coverage from major news organizations
Medicare Weighs Cost, Benefit Of Covering Dendreon's Provenge For Prostate Cancer
Medicare officials are considering whether covering the drug Provenge, used for treating prostate cancer, is worth the cost, The Wall Street Journal reports.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
